CoronaryAtlas logo
CoronaryAtlas
Thromboxane A2
Pathway / Thromboxane amplification

Thromboxane A2

metabolite

Thromboxane A2 amplifies platelet activation and aggregation through COX-1 pathway, driving thrombus formation and coronary occlusion.

Pathway placement
Cascade stepThromboxane amplification
Confidencehigh
RationalePlatelet-derived pro-thrombotic eicosanoid; major platelet aggregation amplifier.
Also acts inPlatelet activation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
54
A — assay feasibility
42
E — evidence strength
70
T1DI (composite)
17
Specificity differential (R−C)+12.5
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuremag 1
2hypertensive emergencymag 2
2high-demand / peri-operative stressn/a
3sudden cardiac deathmag 2
4aPCI-related periproceduralmag 1
4bstent thrombosismag 2
4cin-stent restenosisn/a
5CABG-relatedmag 2
Coverage: 8/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 13 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(4)